Company: VRCA
Filing Date: 2025-07-30
Form Type: 8-K
Source: 0001193125-25-169309
Chunk: 0

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-07-30
Form: 8-K
Item: Item 3.01
Chunk 0
---
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed, on January 24, 2025, The Nasdaq Stock Market LLC (“ Nasdaq”) notified Verrica Pharmaceuticals Inc. (the “ Company”) that, based upon the preceding30-businessday period, the Company no longer satisfied Nasdaq Listing Rule 5450(a)(1), which requires the Company to maintain a minimum closing bid price of $1.00 per share for continued listing on The Nasdaq Global Market (the “ Minimum Bid Price Requirement”). As the Company did not regain compliance with the Minimum Bid Price Requirement within the180-calendarday grace period set forth by Listing Rule 5810(c)(3)(A), by July 23, 2025, Nasdaq notified the Company by letter dated July 24, 2025, that the Company’s securities are subject to delisting from Nasdaq (the “ Staff Determination”) unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the “ Panel”).

The Company intends to timely request a hearing before the Panel. The hearing request automatically stays any suspension or delisting of the Company’s securities and, as a result, the Company expects that its common stock will continue to be listed and traded on The Nasdaq Global Market pending the conclusion of the hearings process.

Pursuant to Listing Rule 5810(c)(3)(H), in order to regain compliance with the Minimum Bid Price Requirement, the closing minimum bid price of the Company’s common stock must be at least $1.00 per share for at least 10 consecutive business days and up to 20 consecutive business days, in Nasdaq staff’s discretion. As previously disclosed, on July 24, 2025, the Company effected a reverse stock split at a ratio of1-for-10. On July 25, 2025, the Company’s common stock began trading on The Nasdaq Global Market on a split-adjusted basis. The primary purpose for the reverse stock split was to increase the per-shareclosing bid price of the Company’s common stock so as to demonstrate compliance with the Minimum Bid Price Requirement and to help ensure the Company’s continued listing on Nasdaq. As of the date hereof, the minimum bid price of the Company’s common stock has been in compliance with the Minimum Bid Price Requirement for four consecutive business days, and the closing bid price of the Company’s common stock was $6.24